Top

Current Neurology and Neuroscience Reports

Published in:

01-01-2018 | Neuro-Oncology (LE Abrey, Section Editor)

Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management

Authors: Christophoros Astaras, Rita de Micheli, Bianca Moura, Thomas Hundsberger, Andreas F. Hottinger

Published in: Current Neurology and Neuroscience Reports | Issue 1/2018

Abstract

Purpose of Review

Immune checkpoint inhibitors represent a major step forward in the field of oncologic immunotherapy these last years and have significantly increased survival of cancer patients in an ever-growing number of indications. These agents block specific immune checkpoint molecules (programmed cell death protein 1 and its ligand as well as cytotoxic T-lymphocyte-associated antigen 4) that normally downregulate the immune response. These new agents show a specific range of adverse effects induced by abnormal immunologic activation.

Recent Findings

Many different neurologic adverse events have been described, including encephalitis, myelopathy, aseptic meningitis, meningoradiculitis, Guillain-Barré-like syndrome, peripheral neuropathy (including mononeuropathy, mononeuritis multiplex, and polyneuropathy) as well as myasthenic syndrome.

Summary

Immune checkpoint inhibitors have shown promising results in cancer but can possibly induce autoimmune disorders. Although rare, neurological adverse events require prompt recognition and treatment to avoid substantial morbidity.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. https://doi.org/10.1038/nrc3239.CrossRefPubMedPubMedCentral

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6. https://doi.org/10.1126/science.271.5256.1734.CrossRefPubMed

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–7. https://doi.org/10.1073/pnas.192461099.CrossRefPubMedPubMedCentral

Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91. https://doi.org/10.1172/JCI80011.CrossRefPubMedPubMedCentral

Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806–12. https://doi.org/10.1097/WCO.0000000000000391.CrossRefPubMed

• Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25. https://doi.org/10.1016/j.ejca.2016.02.024. A comprehensive retrospective analysis of adverse events related to inhibitors of the immune checkpoint PD-1. CrossRefPubMed

•• Kao J C, Liao B, Markovic S N et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017. https://www.ncbi.nlm.nih.gov/pubmed/28873125 A well published series of 10 cases of neurologic adverse events of immune checkpoint inhibitors. The 2 cases of myositis are of particular interest.

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.CrossRefPubMedPubMedCentral

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. https://doi.org/10.1056/NEJMoa1200690.CrossRefPubMedPubMedCentral

10.

Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS. MDX010-20 I. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–82. https://doi.org/10.1002/cncr.27969.CrossRefPubMed

11.

Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–92. https://doi.org/10.1200/JCO.2015.66.1389.CrossRefPubMed

12.

Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–85. https://doi.org/10.1093/annonc/mdx286.CrossRefPubMed

13.

Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. https://doi.org/10.1016/S1470-2045(09)70334-1.CrossRefPubMed

14.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30. https://doi.org/10.1200/JCO.2013.53.0105.CrossRefPubMedPubMedCentral

15.

• Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Ávila ALR, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928–33. https://doi.org/10.1001/jamaneurol.2016.1399. The first report of 2 cases of immune checkpoint inhibitor encephalitis. CrossRefPubMed

16.

Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709–18. https://doi.org/10.1634/theoncologist.2016-0487.CrossRefPubMed

17.

Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8. https://doi.org/10.1016/j.ejca.2016.12.001.CrossRefPubMed

18.

Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55. https://doi.org/10.1056/NEJMoa1611299.CrossRefPubMedPubMedCentral

19.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093.CrossRefPubMed

20.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–85. https://doi.org/10.1016/S1470-2045(16)30364-3.CrossRefPubMedPubMedCentral

21.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. https://doi.org/10.1056/NEJMoa1709937.CrossRefPubMed

22.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/S0140-6736(16)00561-4.CrossRefPubMedPubMedCentral

23.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMedPubMedCentral

24.

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9(1):204. https://doi.org/10.1186/1479-5876-9-204.CrossRefPubMedPubMedCentral

25.

Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–30. https://doi.org/10.1097/CJI.0b013e318156e47e.CrossRefPubMedPubMedCentral

26.

Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011;21(6):530–4. https://doi.org/10.1097/CMR.0b013e32834d3d88.CrossRefPubMed

27.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75. https://doi.org/10.1200/JCO.2009.26.7609.CrossRefPubMedPubMedCentral

28.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824.CrossRefPubMed

29.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefPubMed

30.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17. https://doi.org/10.1016/S0140-6736(14)60958-2.CrossRefPubMed

31.

•• Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42. https://doi.org/10.1093/annonc/mdx225. A comprehensive review of the guidelines for management of immune checkpoint inhibitor therapy by a comprehensive panel of experts. CrossRefPubMed

32.

•• Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–76. https://doi.org/10.1093/annonc/mdw443. A key paper that evaluates the possibility to treat patients with preexisting autoimmune conditions. PubMed

33.

Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28(2):377–85. https://doi.org/10.1093/annonc/mdw558.PubMed

34.

Maul LV, Weichenthal M, Kähler KC, Hauschild A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother. 2016;39(4):188–90. https://doi.org/10.1097/CJI.0000000000000118.CrossRefPubMed

35.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–40. https://doi.org/10.1001/jamaoncol.2015.4368.CrossRefPubMed

36.

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24–32. https://doi.org/10.1016/j.ejca.2016.12.038.CrossRefPubMed

37.

Boisseau W, Touat M, Berzero G, Savatovsky J, Marabelle A, Touitou V, et al. Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. Eur J Cancer. 2017;83:28–31. https://doi.org/10.1016/j.ejca.2017.05.036.CrossRefPubMed

38.

Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82–92. https://doi.org/10.1007/s11102-015-0671-4.CrossRefPubMed

39.

Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371–81. https://doi.org/10.1530/ERC-13-0499.CrossRefPubMedPubMedCentral

40.

Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol. 2012;167(1):1–5. https://doi.org/10.1530/EJE-12-0167.CrossRefPubMed

41.

Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. https://doi.org/10.1126/scitranslmed.3008002.CrossRefPubMed

42.

Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;2016.

43.

Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344(1-2):229–31. https://doi.org/10.1016/j.jns.2014.06.023.CrossRefPubMedPubMedCentral

44.

Schneider S, Potthast S, Komminoth P, Schwegler G, Böhm S. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017;10(2):473–8. https://doi.org/10.1159/000477162.CrossRefPubMedPubMedCentral

45.

Stein MK, Summers BB, Wong CA, Box HL, Cleveland KO. Meningoencephalitis following Ipilimumab administration in metastatic melanoma. Am J Med Sci. 2015;350(6):512–3. https://doi.org/10.1097/MAJ.0000000000000584.CrossRefPubMed

46.

Konoeda F, Suzuki S, Nishimoto Y, Hoshino H, Takagi M. A case of myasthenia gravis and myositis induced by nivolumab. Rinsho Shinkeigaku. 2017;57(7):373–7. https://doi.org/10.5692/clinicalneurol.cn-000991.CrossRefPubMed

47.

Maurice C, Schneider R, Kiehl TR, Bavi P, Roehrl MHA, Mason WP, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015;3(12):1299–302. https://doi.org/10.1158/2326-6066.CIR-15-0141.CrossRefPubMed

48.

Oyanguren B, Sánchez V, González FJ, de Felipe A, Esteban L, López-Sendón JL, et al. Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol. 2013;20(12):1566–70. https://doi.org/10.1111/ene.12249.CrossRefPubMed

49.

Khoja L, Maurice C, Chappell M, MacMillan L, al-Habeeb AS, al-Faraidy N, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016;4(3):175–8. https://doi.org/10.1158/2326-6066.CIR-15-0186.CrossRefPubMed

50.

Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler. 2015;21(5):670. https://doi.org/10.1177/1352458514549403.CrossRefPubMed

51.

LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. J Oncol Pharm Pract. 2017;23(1):71–4. https://doi.org/10.1177/1078155215620922.CrossRefPubMed

52.

Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012;30(6):e76–8. https://doi.org/10.1200/JCO.2011.38.7886.CrossRefPubMed

53.

Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278–80. https://doi.org/10.1136/practneurol-2012-000447.CrossRefPubMed

54.

Oishi K, Nakao M, Maeda S, Matsushita T, Ikeda T, Yamada T, et al. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. Eur J Dermatol. 2017;27(2):193–4. https://doi.org/10.1684/ejd.2016.2943.PubMed

55.

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745. https://doi.org/10.1371/journal.pone.0053745.CrossRefPubMedPubMedCentral

56.

Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017;45:14–7. https://doi.org/10.1016/j.jocn.2017.07.014.CrossRefPubMed

57.

Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol. 2015;35(2):144–7. https://doi.org/10.1097/WNO.0000000000000217.PubMed

58.

Altman AL, Golub JS, Pensak ML, Samy RN. Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngol Head Neck Surg. 2015;153(5):894–5. https://doi.org/10.1177/0194599815606701.CrossRefPubMed

59.

Bompaire F, Mateus C, Taillia H, de Greslan T, Lahutte M, Sallansonnet-Froment M, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30(6):2407–10. https://doi.org/10.1007/s10637-011-9787-1.CrossRef

60.

Manousakis G, Koch J, Sommerville RB, el-Dokla A, Harms MB, al-Lozi MT, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve. 2013;48(3):440–4. https://doi.org/10.1002/mus.23830.CrossRefPubMed

61.

de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375(3):296–7. https://doi.org/10.1056/NEJMc1515584.CrossRefPubMed

62.

Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–3. https://doi.org/10.1093/annonc/mdr028.CrossRefPubMed

63.

Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36(1):77–8. https://doi.org/10.1097/CJI.0b013e31827807dd.CrossRefPubMed

64.

Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589–93. https://doi.org/10.1093/neuonc/nou001.CrossRefPubMedPubMedCentral

65.

Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. Jpn J Clin Oncol. 2016;46(9):875–8. https://doi.org/10.1093/jjco/hyw090.CrossRefPubMed

66.

Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54(1):157–61. https://doi.org/10.1002/mus.25141.CrossRefPubMed

67.

Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016;54(3):506–7. https://doi.org/10.1002/mus.25055.CrossRefPubMed

68.

Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep. 2016;4:2324709616674316.PubMedPubMedCentral

69.

Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78(1):119–22.PubMedPubMedCentral

70.

Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–34. https://doi.org/10.1212/WNL.0000000000004359.CrossRefPubMed

71.

Johnson DB, Saranga-Perry V, Lavin PJ, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33(33):e122–4. https://doi.org/10.1200/JCO.2013.51.1683.CrossRefPubMedPubMedCentral

72.

Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52(2):307–8. https://doi.org/10.1002/mus.24648.CrossRefPubMed

73.

March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2017; 1078155216687389.

74.

Chen YH, Liu FC, Hsu CH, Chian CF. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine (Baltimore). 2017;96(27):e7350. https://doi.org/10.1097/MD.0000000000007350.CrossRef

75.

Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27(3):266–8. https://doi.org/10.1016/j.nmd.2017.01.002.CrossRefPubMed

76.

Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055–8. https://doi.org/10.1111/cas.12961.CrossRefPubMedPubMedCentral

77.

Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–36. https://doi.org/10.1016/j.ejca.2017.05.041.CrossRefPubMed

78.

Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017;27(2):152–4. https://doi.org/10.1097/CMR.0000000000000310.CrossRefPubMed

79.

Chang E, Sabichi AL, Sada YH. Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother. 2017;40(3):114–6. https://doi.org/10.1097/CJI.0000000000000161.CrossRefPubMed

80.

Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299–308. https://doi.org/10.1016/S1470-2045(15)00544-6.CrossRefPubMedPubMedCentral

81.

Lecouflet M, Verschoore M, Giard C, Gohier P, le Corre Y, Milea D, et al. Orbital myositis associated with ipilimumab. Ann Dermatol Venereol. 2013;140(6-7):448–51. https://doi.org/10.1016/j.annder.2013.02.029.CrossRefPubMed

82.

Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016;27(7):1352–3. https://doi.org/10.1093/annonc/mdw126.CrossRefPubMed

83.

Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4(1):36. https://doi.org/10.1186/s40425-016-0139-8.CrossRefPubMedPubMedCentral

84.

Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, Hassel JC. Severe ocular myositis after Ipilimumab treatment for melanoma: a report of 2 cases. J Immunother. 2017;40(7):282–5. https://doi.org/10.1097/CJI.0000000000000178.CrossRefPubMed

85.

Fox E, Dabrow M, Ochsner G. A case of nivolumab-induced myositis. Oncologist. 2016;21(12):e3. https://doi.org/10.1634/theoncologist.2016-0170.CrossRefPubMedPubMedCentral

86.

Saini L, Chua N. Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine. Leuk Lymphoma. 2017;58(8):2011–3. https://doi.org/10.1080/10428194.2016.1265115.CrossRefPubMed

87.

Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol. 2017;28(3):673–5. https://doi.org/10.1093/annonc/mdw655.PubMed

88.

Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7. https://doi.org/10.1200/JCO.2012.41.6750.CrossRefPubMed

Title: Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Authors: Christophoros Astaras
Rita de Micheli
Bianca Moura
Thomas Hundsberger
Andreas F. Hottinger
Publication date: 01-01-2018
Publisher: Springer US
Published in: Current Neurology and Neuroscience Reports / Issue 1/2018
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-018-0810-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content